Lite Strategy's (LITS) Sell (D-) Rating Reiterated at Weiss Ratings

Key Points

• Lite Strategy (LITS) has received a "sell (D-)" rating from Weiss Ratings, indicating a continued lack of confidence in the stock's performance.
• In contrast, Wall Street Zen upgraded Lite Strategy from a "sell" to a "hold" rating, reflecting a slight shift in outlook among analysts.
• The stock is currently priced at $2.50 with a market capitalization of approximately $89.14 million, and has experienced a 1-year price range between $1.46 and $9.00.

Lite Strategy (NASDAQ:LITS - Get Free Report)'s stock had its "sell (d-)" rating reissued by equities research analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen upgraded shares of Lite Strategy from a "sell" rating to a "hold" rating in a report on Friday, October 3rd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of "Sell".

Lite Strategy Trading Up 2.0%

Lite Strategy stock opened at $2.50 on Wednesday. The firm has a market cap of $89.14 million, a PE ratio of -0.53 and a beta of 0.36. Lite Strategy has a 1-year low of $1.46 and a 1-year high of $9.00.

Lite Strategy Company Profile

MEI Pharma, Inc, a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.